Previous Close | 0.6500 |
Open | 0.6500 |
Bid | 0.6800 x N/A |
Ask | 0.7200 x N/A |
Day's Range | 0.6300 - 0.7300 |
52 Week Range | 0.4500 - 3.3500 |
Volume | |
Avg. Volume | 23,264 |
Market Cap | 19.381M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7250 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AWKN.NE
Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its first licensing partnership agreement in Cana
VANCOUVER, British Columbia, August 15, 2022--REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’) to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.
Awakn enters the U.S. addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC